From: Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
Target | Type of Protein | Genetic Aberration | Tumor Types |
---|---|---|---|
EGFR [88] | Tyrosine kinase receptor | Amplification, mutation | Colorectal, lung, gastric, pancreas, liver, lung, others |
HER2 [89] | Tyrosine kinase receptor | Expression | Breast |
ER [90] | Hormone receptor | Expression | Breast, endometrial |
PTEN [91] | Lipid phosphatase | Silencing, allele loss | Glioma, endometrial, prostate, melanoma, breast |
PI3KCA [92] | Serine-threonine kinase | Mutations | Colorectal, breast, lung, brain |
TSC1 [93] | TSC complex protein | Mutation | Bladder |
Serine-threonine kinase | Mutation, silencing | Colorectal, lung | |
K-ras [96] | GTP-binding kinase | Mutation | Colorectal, pancreas, lung, melanoma |
BCR-ABL [97] | Tyrosine kinase | Translocation | CML, ALL |
VHL [98] | Ubiquitin ligase | Loss of heterozygosity, mutation, silencing | Kidney, hemangioblastomas |